New hepatitis c drug combo shows promise in early trial
NCT ID NCT01010646
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a new form of interferon (IFN alfa-2b XL) combined with ribavirin works better and causes fewer side effects than the standard treatment for chronic hepatitis C (genotypes 1 or 4). 84 adults who had not been treated before or had not responded to previous therapy took part. The main goal was to measure how much the virus level dropped after 4 and 12 weeks of treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital de la Croix Rousse
Lyon, 69004, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a cholesterol drug and a bile acid pill help reverse liver scarring?
- Massive study aims to map hepatitis c elimination in pakistan
- Can a blood pressure drug reverse liver damage in hepatitis c?
- New study tests faster hepatitis c detection for drug users
- New hope: hepatitis c drugs after liver cancer treatment
- Blood pressure drug may halt liver damage in hep c patients